Cleared Traditional

K811757 - NEIA PAP ENZYMEIMMUNOASSAY

K811757 is the FDA 510(k) clearance for NEIA PAP ENZYMEIMMUNOASSAY by New England Immunology Assoc.. It is a Class 2 Immunology device (product code JFH) cleared through the Traditional 510(k) pathway after a 52-day FDA review.

K811757 · New England Immunology Assoc. · Immunology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Aug 1981
Decision
52d
Days
Class 2
Risk

K811757 is an FDA 510(k) clearance for the NEIA PAP ENZYMEIMMUNOASSAY. Classified as Acid Phosphatase (prostatic), Tartrate Inhibited (product code JFH), Class II - Special Controls.

Submitted by New England Immunology Assoc. (Mchenry, US). The FDA issued a Cleared decision on August 13, 1981 after a review of 52 days - a notably fast clearance cycle.

This device falls under the Immunology FDA review panel, regulated under 21 CFR 862.1020 - the FDA immunology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all New England Immunology Assoc. devices

Submission Details

510(k) Number K811757 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received June 22, 1981
Decision Date August 13, 1981
Days to Decision 52 days
Submission Type Traditional
Review Panel Immunology (IM)
Summary -
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
52d faster than avg
Panel avg: 104d · This submission: 52d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code JFH Acid Phosphatase (prostatic), Tartrate Inhibited
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 862.1020
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Immunology devices follow this clearance model.

Regulatory Peers - JFH Acid Phosphatase (prostatic), Tartrate Inhibited

All 29
Devices cleared under the same product code (JFH) and FDA review panel - the closest regulatory comparables to K811757.
CORDIA PAP
K831105 · Cordis Corp. · May 1983
ABBOTT PAP-EIA
K812925 · Abbott Laboratories · Jan 1982
TANDEM PAP KIT - (PARTS I & II)
K811959 · Hybritech, Inc. · Sep 1981
PROSTATIC ACID PHOSPHATASE RADIOIMM. KIT
K811274 · Bd Becton Dickinson Vacutainer Systems Preanalytic · May 1981
PROSTATIC ACID PHOSPHATASE (PAP) RDA KIT
K811169 · Amersham Corp. · May 1981
ESKACHEM PAP REAGENT
K803234 · Smithkline Diagnostics, Inc. · Feb 1981